Anamorelin in the Management of Cancer Cachexia: Clinical Efficacy, Challenges, and Future Directions
Anticancer Research · 2025
DOI: 10.21873/anticanres.17475 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Anticancer Research, 2025. Verfasst von Hironori Fujii und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Gifu University Hospital, Gifu, Japan; fujii.hironori.u5@f.gifu-u.ac.jp. Hauptthemen laut MEDLINE: Cachexia, Neoplasms, Hydrazines, Oligopeptides. Die Arbeit wurde bisher 12-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Gifu University Hospital, Gifu, Japan; fujii.hironori.u5@f.gifu-u.ac.jp.
- Laboratory of Community Pharmaceutical Practice and Science, Gifu Pharmaceutical University, Gifu, Japan.
- Department of Pharmacy, Gifu University Hospital, Gifu, Japan.
- Laboratory of Advanced Medical Pharmacy, Gifu Pharmaceutical University, Gifu, Japan.
Zitieren
APA
Fujii, H., Yamada, Y., Iihara, H., Kobayashi, R., & Suzuki, A. (2025). Anamorelin in the Management of Cancer Cachexia: Clinical Efficacy, Challenges, and Future Directions. Anticancer Research. https://doi.org/10.21873/anticanres.17475
Vancouver
Fujii H, Yamada Y, Iihara H, Kobayashi R, Suzuki A. Anamorelin in the Management of Cancer Cachexia: Clinical Efficacy, Challenges, and Future Directions. Anticancer Research. 2025. doi:10.21873/anticanres.17475
BibTeX
@article{Fujii2025,
author = {Fujii, Hironori and Yamada, Yunami and Iihara, Hirotoshi and Kobayashi, Ryo and Suzuki, Akio},
title = {Anamorelin in the Management of Cancer Cachexia: Clinical Efficacy, Challenges, and Future Directions},
journal = {Anticancer Research},
year = {2025},
doi = {10.21873/anticanres.17475}
}
EUVIMED